NOV 1 7 2006 8

IFW

PTO/SB/21 (09-06 Approved for use through 03/31/2007, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number **Application Number** 10/587,678 TRANSMITTAL Filing Date July 27, 2006 First Named Inventor **FORM** 10/587,678 Art Unit Unknown **Examiner Name** Unknown (to be used for all correspondence after initial filing) Attorney Docket Number 01435.035US1 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a Proprietary Information After Final **Provisional Application** Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Identify **Terminal Disclaimer Extension of Time Request** below): Form 1449 (1 pg.); Copies of 26 cited Request for Refund **Express Abandonment Request** references; Return Postcard CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name VIKSNINS HARRIS & PADYS PLLP Signature Printed name Robert J. Harris Date Reg. No. November / 4, 2006 37,346 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature Date November // Typed or printed name

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

N 10/587.678

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

NOV 1 7 200 niolicant:

Kathryn E. Uhrich et al.

Examiner:

Unknown Unknown

erial No.:

10/587,678

Group Art Unit: Docket:

01435.035US1

iled: Title:

July 27, 2006 AMPHIPHILIC STAR-LIKE OR SCORPION-LIKE MACROMOLECULES, VARIOUS

COMPOSITIONS AND USES THEREOF

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seq., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicants request that a copy of the Form 1449, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. § 1.97, no fee or statement is required with the Information Disclosure Statement. However, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 503503 in order to have this Information Disclosure Statement considered. The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

> Respectfully submitted, Kathryn E. Uhrich et al. By their Representatives, Viksnins Harris & Padys PLLP P.O. Box 111098 St. Paul, MN 55111-1098 952 876-4094

Date //-/4-06

Robert J. Harris

Reg. No. 37,346

CERTIFICATE UNDER 37 CFR 1.8: I hereby certify that this correspondence is being transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment; Commissioner for Patents; P.O. Box 1450, Alexandria, VA 22313-1450, on this 14 day of November 2006.

Substitute for form 1449A/PTO and/or 1449B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	10/587,678
(Like as many sheet); as necessary)	Filing Date	07/27/06
%	First Named Inventor	Kathryn E. Uhrich
(NOV 1 7 2006 g)	Group Art Unit	Unknown
Sheet 1 of 1	Examiner Name	Unknown
	Attorney Docket No: 0	1435.035US1

FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Foreign Document Number (include country code)	Publication Date	Translation (Abstract Only or Full Translation, if applicable)	
	WO 03/103594	Dec. 18, 2003		
	WO 03/005959	Jan. 23, 2003		
The second second framework and a	WO 00/65024	Nov. 2, 2000		
	WO 03/103594	Dec. 18, 2003		

Examiner Initials*	OTHER DOCUMENTS NON PATENT LITERATURE DOCUMENTS Include last name of the first author (in CAPITAL letters), "Title of the Article", Title of the Source (book, magazine, journal, serial, symposium, catalog, etc.), Volume-Number, page(s) and (date).		
	International PCT Search Report for PCT/US 05/002900, (08/08/2005), 5 pgs.		
	Allen et al., Colloids Surf., B: Biointerfaces (1999) 16:3-27.		
	Camejo et al., Atherosclerosis Supplements, (2002) 3:3-9.		
	Cammas et al., Macromol. Chem. Phys. (1995) 196:1899-1905.		
	Chnari et al., Biomaterials, (2005) 26:3749-3758.		
	Djordjevic, J. et al. <u>AAPS Pharmsci</u> (2003) 5(4):1-12.		
	Gao et al., Macromolecules, (1993) 26:7353-7360.		
	Gitsov et al., J. Polym. Sci., Part A: Polym. Chem. (2000) 38:2711-2727.		
-	Kreig et al., J. Chem. Phys. (2001) 115:6243-6251.		
	Liu, H. et al. J. Polymer Sci.: Part A: Polymer Chem. (1999) 37:703-711.		
	Moghimi et al., J. Pharm. Rev. (2001) 53(2):283-318.		
	Moghimi, S. M., Adv. Drug Delivery Rev. (1995) 17:1.		
	Moore, J.S. et al. Macromolecules (1990) 23(1):65-70.		
	Otsuka et al., Curr. Opin. Colloid Interface Sci. (2001) 6:3-10.		
	Papisov, Adv. Drug Delivery Rev. (1995) 16:127-139.		
	Rousselle C., et al., Mol. Pharmacol. (2000) 57(4):679-686.		
	Schmalenberg et al., Biomacromolecules (2001) 2:851-855.		
	Temsamani, et al., <u>PSTT</u> , (2000) 3(5):155-162.		
	Tian et al., Macromolecules, (2004) 37:538-543.		
	Tian, L. "Novel Amphiphilic macromolecules for drug delivery applications: Design,		
	Synthesis and Characterization" in Dissertation, New Brunswick, New Jersey (2004), pp. 13-48, 114-138, 160-175.		
	Wiliams et al., Arteriosclerosis, Thrombosis & Vascular Biology, (1995) 15(5):551-561.		
	Zhu et al., J. Polym. Sci. Polm. Chem., (1989) 27,:2151.		

EXAMINER

DATE CONSIDERED